Lauren C. Y. Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren C. Y. Tang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adam Testro
Victorian Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
1 shared publication - Audrey Z. Fu
Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
1 shared publication - Avik Majumdar
Victorian Liver Transplant Unit, Austin Health, Melbourne, Australia
1 shared publication - Danny Con
Faculty of Medicine, Dentistry and Health Sciences The University of Melbourne Parkville Australia
1 shared publication - David Geoffrey Bowen
Australian National Liver Transplant Unit Royal Prince Alfred Hospital Camperdown New South Wales Australia
1 shared publication - Emily Nash
Australian National Liver Transplant Unit Royal Prince Alfred Hospital Camperdown New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by Wiley in Anz Journal of Surgery
Impact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation
Background: The risks of recurrent hepatocellular carcinoma (HCC) and HCC‐specific mortality post‐liver transplant (LT) are influenced by the number and size of viable tumours. This study assesses HCC‐specific mortality post‐transplant for patients in two groups—those with no viable disease versus single viable tumour ≤ 3 cm, as assessed on most recent imaging prior to transplantation. Methods: This retrospective cohort study included adult patients transplanted for the indication of HCC between 1998 and 2018 at two Australian centres. Competing risks regression assessed 5‐year HCC‐specific mortality, with the competing risk of non‐HCC‐specific mortality. Results: There was a significantly lower 5‐year HCC‐specific mortality post‐transplant for those with no viable disease ( n = 152) versus single viable tumour ≤ 3 cm ( n = 145) (4.0% vs. 10.5%, SHR 2.72, 95% CI: 1.06–6.98, p = 0.038) on univariable analysis. On multivariable competing risks analysis, the modified Response Evaluation Criteria In Solid Tumour (mRECIST) criteria and higher AFP level at transplant were significant predictors of 5‐year HCC specific mortality, with progressive disease (aSHR 16.33, 95% CI: 2.35–113.6, p = 0.005) and stable disease (aSHR 10.26, 95% CI: 1.81–58.2, p = 0.0012) having a higher risk than complete response; whilst the significance of no viable disease versus single viable tumour ≤ 3 cm was not significant on multivariable analysis. Conclusions: There was a significantly lower 5‐year HCC‐specific mortality for those with imaging showing no viable disease versus single viable tumour ≤ 3 cm, prior to transplantation. Lower HCC‐specific mortality was demonstrated for those with a lower AFP level and those in radiological complete response at time of transplant.
- 20 September 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessImpact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation
Background: The risks of recurrent hepatocellular carcinoma (HCC) and HCC‐specific mortality post‐liver transplant (LT) are influenced by the number and size of viable tumours. This study assesses HCC‐specific mortality post‐transplant for patients in two groups—those with no viable disease versus single viable tumour ≤ 3 cm, as assessed on most recent imaging prior to transplantation. Methods: This retrospective cohort study included adult patients transplanted for the indication of HCC between 1998 and 2018 at two Australian centres. Competing risks regression assessed 5‐year HCC‐specific mortality, with the competing risk of non‐HCC‐specific mortality. Results: There was a significantly lower 5‐year HCC‐specific mortality post‐transplant for those with no viable disease ( n = 152) versus single viable tumour ≤ 3 cm ( n = 145) (4.0% vs. 10.5%, SHR 2.72, 95% CI: 1.06–6.98, p = 0.038) on univariable analysis. On multivariable competing risks analysis, the modified Response Evaluation Criteria In Solid Tumour (mRECIST) criteria and higher AFP level at transplant were significant predictors of 5‐year HCC specific mortality, with progressive disease (aSHR 16.33, 95% CI: 2.35–113.6, p = 0.005) and stable disease (aSHR 10.26, 95% CI: 1.81–58.2, p = 0.0012) having a higher risk than complete response; whilst the significance of no viable disease versus single viable tumour ≤ 3 cm was not significant on multivariable analysis. Conclusions: There was a significantly lower 5‐year HCC‐specific mortality for those with imaging showing no viable disease versus single viable tumour ≤ 3 cm, prior to transplantation. Lower HCC‐specific mortality was demonstrated for those with a lower AFP level and those in radiological complete response at time of transplant.
- Open Access
- 24 February 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (10) , 1400-1412
Pulmonary function test parameters before liver transplantation predict post-transplant survival and respiratory-related death
Pulmonary function tests (PFTs) are performed ahead of listing for liver transplantation (LT) to assess respiratory fitness for transplantation. We aimed to establish whether pre-transplant PFTs were associated with post-LT overall survival and respiratory cause of death. A single-center retrospective study of patients transplanted between 2014 and 2023 was performed. Cox regression was used to analyze the relationship between PFT parameters, normalized for age, sex, ethnicity, and overall post-transplant survival. Competing risks regression was used to analyze the relationship between PFT parameters and respiratory death post-LT. Pre-transplant PFTs from 772 LT recipients were studied (33% female, median age 58 y, indication for transplant: alcohol-associated liver disease in 28.3%, metabolic dysfunction–associated steatotic liver disease in 18.0%). When combined with clinical variables, PFT parameters were predictive of post-transplant overall survival and respiratory death. Lower forced expiratory volume in 1 second (FEV1) (aHR 0.85, 95% CI 0.73–0.99, p =0.04), increased age at transplant (aHR 1.03, 95% CI 1.01–1.05, p =0.01), and current smoking at time of assessment (aHR 1.95, 95% CI 1.08–3.54, p =0.03) were independently associated with poorer post-transplant survival. Whereas both single-breath diffusing capacity of the lung (DLCO SB) (aSHR 0.66, 95% CI 0.52–0.82, p p =0.001) were independent predictors of post-LT respiratory cause of death. In conclusion, a lower FEV1 z -score was independently associated with poorer post-LT overall survival, and a lower DLCO SB z -score was associated with respiratory cause of death post-LT, supporting the routine use of PFTs in pre-liver transplant assessment.
- 24 February 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (10) , 1400-1412
Open AccessPulmonary function test parameters before liver transplantation predict post-transplant survival and respiratory-related death
Pulmonary function tests (PFTs) are performed ahead of listing for liver transplantation (LT) to assess respiratory fitness for transplantation. We aimed to establish whether pre-transplant PFTs were associated with post-LT overall survival and respiratory cause of death. A single-center retrospective study of patients transplanted between 2014 and 2023 was performed. Cox regression was used to analyze the relationship between PFT parameters, normalized for age, sex, ethnicity, and overall post-transplant survival. Competing risks regression was used to analyze the relationship between PFT parameters and respiratory death post-LT. Pre-transplant PFTs from 772 LT recipients were studied (33% female, median age 58 y, indication for transplant: alcohol-associated liver disease in 28.3%, metabolic dysfunction–associated steatotic liver disease in 18.0%). When combined with clinical variables, PFT parameters were predictive of post-transplant overall survival and respiratory death. Lower forced expiratory volume in 1 second (FEV1) (aHR 0.85, 95% CI 0.73–0.99, p =0.04), increased age at transplant (aHR 1.03, 95% CI 1.01–1.05, p =0.01), and current smoking at time of assessment (aHR 1.95, 95% CI 1.08–3.54, p =0.03) were independently associated with poorer post-transplant survival. Whereas both single-breath diffusing capacity of the lung (DLCO SB) (aSHR 0.66, 95% CI 0.52–0.82, p p =0.001) were independent predictors of post-LT respiratory cause of death. In conclusion, a lower FEV1 z -score was independently associated with poorer post-LT overall survival, and a lower DLCO SB z -score was associated with respiratory cause of death post-LT, supporting the routine use of PFTs in pre-liver transplant assessment.